/ /

  • linkedin
  • Increase Font
  • Sharebar

    Microstent approval makes big news in glaucoma world


    “Implanted using a non-perforating ab interno approach, this device is placed at the base of the scleral spur and slides nicely into the subconjunctival space,”  said Steven D. Vold, MD. “For surgeons...who have not done a lot of angle surgery, the CyPass might be a good alternative.”

    Dr. Vold, who is in private practice in Fayetteville, AR, is a consultant to Transcend Medical and Alcon Laboratories.

    Recent: Glaucoma risk may increase after cataract removal in early infancy


    The device is contraindicated in eyes with angle closure glaucoma and eyes with traumatic, malignant, uveitis, neovascular glaucoma, and eyes with discernible congenital anomalies of the anterior chamber angle.   

    The randomized clinical trial compared patients with cataract surgery paired with the device to patients in a cataract surgery group.

    More: Check out a recap from the 2016 Glaucoma 360 gala!

    Common post-operative adverse events included:

    • Loss of BCVA of 10 or more letters at 3 months after surgery (8.8% for the device group and 15.3% for cataract surgery group)
    • Anterior chamber cell and flare requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%)
    • Worsening visual field mean deviation by 2.5 or more decibels (6.7% vs. 9.9%)

    Related: 7 common mistakes in managing uveitic glaucoma

    • IOP increase of 10 or more mm Hg 30 or more days after surgery (4.3% vs. 2.3%)
    • Corneal edema 30 or more days after surgery or severe in nature (3.5% vs. 1.5%)

    Video of mechanism

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results